Aerbio has publicized its Series A fundraising plan of securing up to €50 million to propel next-generation sustainable biotechnology. The company states that the funds raised in this round will be crucial in completing its demonstration-scale facility.
One of the pioneers in sustainable biotechnology, Aerbio has announced its plans to raise up to €50 million in a Series A funding round, with the target close set for Q4 2024. This bold step forward will reportedly fund the construction of Aerbio’s cutting-edge demonstration-scale facility and expand the company’s revolutionary (R)evolve™ platform, setting the stage for full-scale commercial operations.
REVOLUTIONIZING BIOTECHNOLOGY FOR A SUSTAINABLE FUTURE
Aerbio is at the forefront of biotechnology innovation, transforming simple molecules into valuable products without the need for arable land or fossil fuels. With its groundbreaking (R)evolve™ platform, the company points out it has unlocked the potential of microbiology to convert carbon dioxide and hydrogen into valuable products. Aerbio’s launching product is Proton™, a protein-rich ingredient poised to revolutionise food and animal nutrition industries.
“Our ambition knows no bounds,” says Kaspar Kristiansen, CEO of Aerbio. “Our Series A round is a bold statement in our conviction in our plan and our relentless pursuit of breaking new ground in biotechnology. We’re not just building a company—we’re turning biotechnology on its head, paving the way for a sustainable future where sugar-free fermentation is a reality.”
PROPELLING THE FUTURE OF SUSTAINABLE PROTEIN
The company explains that the funds raised in this round will be crucial in completing Aerbio’s demonstration-scale facility, a pivotal milestone in its journey. This facility will provide the final validation needed before scaling up to full commercial operations. With the successful launch of its pilot facility and the recent appointment of board members, Aerbio points out that it has strong foundations build upon, with its ambition to not just become a market in sustainable protein solutions, but in the field of industrial biotechnology.
Aerbio adds: “As the world increasingly turns towards sustainable alternatives, the market potential for Proton™ and other products in our pipeline is immense. The demonstration facility will accelerate our ability to bring Proton™ to market, whilst in parallel our R&D work on platform expansion will ensure that Aerbio remains at the cutting edge of the industry.”
